Latest news with #CorceptTherapeutics
Yahoo
4 days ago
- Business
- Yahoo
Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT submitted an FDA application for relacorilant to treat platinum-resistant ovarian cancer, based on promising Phase 2 and 3 trial data. A professional scientist in a laboratory, visually demonstrating the development of Microbiome therapeutics platform. Patients receiving the drug with nab-paclitaxel experienced notable improvements in survival outcomes without added safety risks. With relacorilant already designated as an orphan drug and a decision date set for December 30, 2025, this milestone marks Corcept's second active NDA submission. Relacorilant modulates cortisol activity via glucocorticoid receptors and has shown strong clinical potential. Backed by robust financials, including a 128% stock return over the past year and a current ratio of 3.07, Corcept is well-positioned to target the estimated 20,000 U.S. patients needing new therapies for platinum-resistant disease annually. If approved, this drug could significantly enhance treatment options and expand the company's oncology portfolio. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharma firm specializing in therapies that regulate cortisol, a key hormone in body function. Its lead product, Korlym, is FDA-approved for treating Cushing's syndrome, a condition caused by excess cortisol. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the . Analysts are reiterating their Buy rating for the stock amid advancements in ovarian cancer treatment. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company specializing in cortisol modulation by developing compounds that antagonize the glucocorticoid receptor. Based in California, the company treats Cushing's syndrome with its commercial drug Korlym. The company advances a pipeline of over 30 clinical-stage molecules for endocrinology, oncology, metabolism, and neurology. On July 14, 2025, the company announced that it had filed for a new drug application to the U.S. FDA for relacorilant. Relacorilant is a selective cortisol modulator for treating platinum-resistant ovarian cancer. The submission follows the positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. The trials indicated that relacorilant combined with nab-paclitaxel offers improved progression-free and overall survival, without increasing the safety burden of the patients. Since platinum-resistant ovarian cancer currently has limited therapies, the FDA approval for relacorilant has high expectations. Amid this advancement in Corcept Therapeutics Incorporated (NASDAQ:CORT)'s relacorilant, Piper Sandler and H.C. Wainwright reiterated their Buy rating on the stock. Piper Sandler maintains a price target of $131 while H.C. Wainwright has set the price target at $145. With an impressive projected 5-year EPS growth of 69.48% and a low beta of 0.21, Corcept Therapeutics Incorporated (NASDAQ:CORT) promises an attractive investment for those seeking high growth at low risk. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10-07-2025
- Business
- Business Insider
Piper Sandler pharmaceuticals analyst holds analyst/industry conference call
Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)' Relacorilant in ovarian cancer on an Analyst/Industry conference call to be held on July 10. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
07-07-2025
- Business
- Yahoo
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 2, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced pivotal data from its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the American Society of Clinical Oncology Annual Meeting. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. According to the release, ROSELLA met its primary endpoint of improved progression-free survival according to assessment by blinded independent central review (PFS-BICR). A 30% reduction in disease progression risk was recorded in patients who received relacorilant in addition to nab-paclitaxel chemotherapy as compared to those who received nab-paclitaxel monotherapy only. The results also showed that relacorilant plus nab-paclitaxel was well-tolerated and exhibited a comparable safety profile between treatment arms. Adding relacorilant did not cause a rise in patients' safety burden. In fact, patients who were administered relacorilant plus nab-paclitaxel experienced a lower incidence of ascites (5.3%) compared to those who received nab-paclitaxel alone (10.5%). The occurrence of abdominal paracenteses during treatment was also lower for the former patients. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company's flagship product, Korlym, is FDA-approved for the treatment of Cushing's syndrome, a disorder characterized by excessive cortisol production. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
04-07-2025
- Business
- Yahoo
Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best NASDAQ growth stocks to buy for the next 3 years. On June 24, Corcept Therapeutics announced positive results from the CATALYST trial of Korlym (mifepristone). The data was presented at the American Diabetes Association's 85th Scientific Sessions and also published in Diabetes Care. It showed that Korlym improved glucose control in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes. The trial met its primary endpoint, as patients receiving Korlym experienced a 1.47% decrease in HbA1c from baseline, as compared to a 0.15% decrease in the placebo group. Those on a 900mg dose saw a 2.01% HbA1c improvement. Beyond blood sugar, Korlym also led to reductions in body weight (by 5.1 kg) and waist circumference (by 5.1 cm), even as patients reduced or stopped other glucose-lowering medications. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. The CATALYST trial is the largest to date investigating hypercortisolism in difficult-to-control type 2 diabetes. Its initial phase screened 1,057 patients and found that 24% had hypercortisolism, which made them eligible for the treatment phase. Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
